What is efpeglenatide? Structure, research and status

Efpeglenatide is a long-acting GLP-1 receptor agonist that joins a modified exendin-4 peptide to a fragment of a human antibody. Hanmi Pharmaceutical of South Korea developed it.

Complete guide10 min read

Key takeaway

Efpeglenatide links an exendin-4 analog to a human IgG4 Fc fragment through a polyethylene glycol chain. In AMPLITUDE-O, a trial of 4,076 adults with type 2 diabetes and heart or kidney disease, major cardiovascular events occurred in 7.0% on efpeglenatide and 9.2% on placebo. Gastrointestinal events were the most common side effects across its trials.

At a glance

Article typeComplete guide
Regulatory statusIn clinical trials“Efpeglenatide is not approved by the FDA for any use.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited9 in this article · 9 across 1 article on Efpeglenatide
Related productsIncretin analogs

Efpeglenatide, development code HM11260C, was licensed to Sanofi in 2015 and tested in five phase 3 AMPLITUDE trials. Sanofi discontinued its work in 2020, and Hanmi continued alone. South Korea approved efpeglenatide for chronic weight management on October 7, 2026. FDA has not approved it.

Quick answer: Efpeglenatide is a GLP-1 receptor agonist approved in South Korea but not in the United States. Efpeglenatide is not approved by the FDA for any use. Its Korean approval covers weight management in adults without diabetes. Material sold under the name for research is not an approved medicine.

Vitrapep does not sell efpeglenatide; this page is a reference summary of published research and regulatory information.

What is efpeglenatide and how is it built?

FDA's Global Substance Registration System describes efpeglenatide as a fusion protein with three parts [1]. The first is a 39-amino-acid peptide with the sequence of exendin-4, found in Gila monster venom. Exenatide, covered in Vitrapep's exenatide complete guide, is a synthetic version of that peptide.

In efpeglenatide, the first amino acid of exendin-4, histidine, is replaced by imidazoleacetic acid [1]. A 2025 analysis with Hanmi-affiliated authors calls this modified peptide CA-exendin-4 [3]. The second part is the Fc fragment of human immunoglobulin G4 (IgG4), the stem region of an antibody. It has two chains of 221 amino acids joined by a disulfide bond [1].

The third part is a polyethylene glycol (PEG) linker. It connects lysine 27 of the peptide to the first amino acid of one Fc chain [1]. The 2025 analysis names Hanmi's linker platform LAPSCOVERY [3].

Table 1

What is efpeglenatide and how is it built

PropertyEfpeglenatide
ClassLong-acting GLP-1 receptor agonist; peptide joined to an antibody Fc fragment [1], [3]
Peptide partExendin-4 (39 amino acids) with imidazoleacetic acid in place of histidine 1 and an amidated end [1]
CarrierHuman IgG4 Fc fragment: two 221-amino-acid chains joined by a disulfide bond [1]
LinkerPolyethylene glycol chain from lysine 27 of the peptide to one Fc chain [1]
Molecular formulaC2398H3677N630O742S17, an FDA estimate that leaves out the linker [1]
Molecular weightAbout 54,000 Da, an FDA estimate that leaves out the linker [1]
PubChemSubstance records only; no computed compound record (PubChem)
Other names and codesHM11260C (Hanmi), SAR439977 (Sanofi), langlenatide; CAS 1296200-77-5; UNII 3M1V5Z2270 [1]
Half-life in patientsGeometric mean of 135 to 180 hours in two phase 2 studies [2]
DeveloperHanmi Pharmaceutical; licensed to Sanofi until Sanofi discontinued development in 2020 [10]
ApprovalsSouth Korea, October 7, 2026 [12]; none from FDA (no Drugs@FDA record in openFDA on November 18, 2026)

A 2020 FDA rule treats any amino acid chain longer than 40 amino acids as a protein, a category of biological product (Federal Register). Each efpeglenatide Fc chain has 221 [1].

How does efpeglenatide work?

FDA's substance record lists efpeglenatide as a GLP-1 receptor agonist [1]. Vitrapep's guide to how GLP-1 receptor agonists work explains that receptor's signaling. Korea's Ministry of Food and Drug Safety (MFDS) said the drug acts on GLP-1 receptors in the hypothalamus, medulla and gut. These actions suppress appetite and delay stomach emptying, prolonging fullness [12].

Long action. In two phase 2 studies in adults with type 2 diabetes, the geometric mean half-life ranged from 135 to 180 hours [2]. A pooled analysis of six studies estimated low clearance and linked it to the Fc fragment. Fc-fusion proteins are recycled through the neonatal Fc receptor, which limits their breakdown [3]. The authors noted similarly low clearance for dulaglutide, another Fc-based GLP-1 receptor agonist [3].

Stomach emptying. A phase 1b study randomized 47 adults with type 2 diabetes to efpeglenatide, placebo or liraglutide [4]. At peak drug levels, one efpeglenatide regimen delayed gastric emptying about as much as liraglutide, meeting a noninferiority test. A second regimen slowed emptying less [4].

Antibodies. In EXCEED 203, a 12-week phase 2 trial of 254 adults with early type 2 diabetes, no neutralizing antibodies to efpeglenatide were detected [5].

What is efpeglenatide approved for, and what is it being studied for?

South Korea. MFDS approved efpeglenatide on October 7, 2026, under the brand name Eppe (에페) [12]. The approved use is chronic weight management in adults with obesity or overweight who do not have diabetes, alongside a reduced-calorie diet and exercise [12]. MFDS called it the 45th new drug developed in Korea and the first Korean-developed GLP-1 class obesity drug [12].

United States and Europe. With no FDA label, there is no section 1 indication to cite. EMA's downloadable list of human medicines did not include efpeglenatide on that date (EMA).

Registered trials. ClinicalTrials.gov listed one recruiting efpeglenatide trial on November 18, 2026. NCT07379333 is a Korean phase 3 trial in an estimated 118 adults with type 2 diabetes on metformin and dapagliflozin. Its primary outcome is HbA1c change at 36 weeks.

The obesity trial behind the Korean approval, NCT06174779, was completed on March 13, 2026, with no posted results. Vitrapep's guide on how to find a peptide clinical trial explains these records.

What did the key efpeglenatide trials show?

AMPLITUDE-O (NCT03496298) enrolled 4,076 adults with type 2 diabetes at 344 sites in 28 countries [7]. Each had cardiovascular disease or kidney disease, plus at least one other cardiovascular risk factor. Mean age was 64.5 years, and 33% were women (Gerstein et al., 2021).

Major adverse cardiovascular events occurred in 7.0% on efpeglenatide and 9.2% on placebo over a median 1.81 years. A kidney composite outcome occurred in 13.0% versus 18.4% (hazard ratio 0.68; 95% CI, 0.57 to 0.79) [7]. In an exploratory analysis, these effects did not differ by baseline use of SGLT2 inhibitors [14].

The design paper planned to continue until at least 330 participants had a major event (Gerstein et al., 2021). The published analysis counted 314 [7]. ClinicalTrials.gov lists the trial as terminated by a sponsor decision that it says was not related to safety.

AMPLITUDE-M (NCT03353350) tested efpeglenatide alone in 406 adults with type 2 diabetes managed by diet and exercise. At week 30, placebo-adjusted HbA1c reductions ranged from 0.5 to 1.0 percentage points across three efpeglenatide groups [8].

AMPLITUDE-D (NCT03684642) compared efpeglenatide with dulaglutide in 908 adults on metformin. Weight fell about 3 kg in all groups [9]. The sponsor ended AMPLITUDE-D, -L and -S early for funding reasons, not safety or efficacy concerns [9].

The Korean obesity trial enrolled 448 adults without diabetes [11]. At week 40, at least 5% weight loss occurred in 79.42% on efpeglenatide versus 14.49% on placebo [11].

Table 2

What did the key efpeglenatide trials show

TrialPopulation and sizeDesign and lengthPrimary result
AMPLITUDE-O, 2021 [7]4,076 adults with type 2 diabetes and cardiovascular or kidney diseaseDouble-blind, placebo-controlled; median 1.81 yearsMajor cardiovascular events 7.0% vs 9.2%; hazard ratio 0.73 (95% CI, 0.58 to 0.92)
AMPLITUDE-M, 2022 [8]406 adults with type 2 diabetes on diet and exercise aloneDouble-blind, placebo-controlled; primary end point at 30 weeksHbA1c reduction superior to placebo in all three efpeglenatide groups
AMPLITUDE-D, 2023 [9]908 adults with type 2 diabetes on metforminRandomized versus dulaglutide; 56 weeks; stopped earlyHbA1c reduction noninferior to dulaglutide
Korean phase 3, 2025 topline [11]448 Korean adults with obesity and no diabetesDouble-blind, placebo-controlled; 40-week interim of a 64-week trialBody weight -9.75% vs -0.95%; company release, not peer reviewed

All four are human trials; the Korean figures come from a company release, not a journal. Vitrapep's guide on how to evaluate peptide research explains why that matters.

What side effects were reported in efpeglenatide trials?

With no US label, efpeglenatide has no FDA section 6 or boxed warning. The MFDS approval notice did not list adverse reactions [12].

Table 3

What side effects were reported in efpeglenatide trials

EventAMPLITUDE-O efpeglenatide (N=2,718)AMPLITUDE-O placebo (N=1,355)AMPLITUDE-D efpeglenatide (N=605)AMPLITUDE-D dulaglutide (N=302)
Nausea13.4%3.8%27.8%25.8%
Diarrhea8.6%4.7%29.1%29.8%
Vomiting5.9%1.3%14.2%12.3%
Decreased appetite5.3%1.1%14.5%11.9%
Serious adverse events21.6%22.0%7.1%6.6%

Source: ClinicalTrials.gov results for NCT03496298 and NCT03684642; efpeglenatide groups pooled by Vitrapep. Populations and follow-up differ, so the two trials' rates are not directly comparable.

Gastrointestinal events. In AMPLITUDE-O, diarrhea, constipation, nausea, vomiting or bloating occurred more often with efpeglenatide [7]. The registry shows 5.4% stopped efpeglenatide because of adverse events, versus 3.6% on placebo. In EXCEED 203, nausea and vomiting subsided after the first 2 weeks [5].

In BALANCE, a 20-week phase 2 trial of 297 adults without diabetes, placebo-adjusted weight loss ranged from 6.3 to 7.2 kg. Discontinuations due to adverse events ranged from 5% to 19% across efpeglenatide groups [6].

Low blood sugar. The AMPLITUDE-O registry lists hypoglycemia in 4.6% on efpeglenatide and 2.7% on placebo. Level 2 hypoglycemia, a clinically significant low, reached up to 10% in AMPLITUDE-L, where participants also used basal insulin [9].

Hanmi's Korean trial. Hanmi reported fewer gastrointestinal events than published rates for marketed GLP-1 obesity medicines [11]. That is a cross-trial comparison, and no rates were given.

Not reported is not absent. The sources reviewed here give no rates of pancreatitis, gallbladder disease or thyroid tumors for efpeglenatide. One exploratory AMPLITUDE-O analysis found that efpeglenatide changed lipase and amylase, two pancreatic enzymes (Raaschou-Oddershede et al., 2026).

What is the regulatory status of efpeglenatide?

United States. Efpeglenatide has no FDA approval. FDA's substance registry assigns it UNII 3M1V5Z2270, an identifier that does not signal approval [1].

Development history. Sanofi announced a worldwide license from Hanmi on November 5, 2015, covering efpeglenatide and two other diabetes candidates (Sanofi 20-F, 2016). Sanofi's 2020 annual report lists efpeglenatide as discontinued and the Hanmi collaboration as ended [10].

South Korea. MFDS approved efpeglenatide on October 7, 2026 [12]. Hanmi said it completed the application on December 17, 2025, and announced a Mexico distribution deal in January 2026 (Hanmi, 2026). Its Mexican partner is responsible for seeking approval there.

Sport. The WADA 2026 Prohibited List does not name efpeglenatide or GLP-1 receptor agonists [13]. Its S0 class prohibits substances not covered elsewhere that lack any government approval for human therapeutic use [13].

Research-labeled products. A research-use-only label does not make a product approved, legal or safe for people. See research peptides and human-use risks and why research peptides have no dose.

What is still unknown about efpeglenatide?

Full 64-week results of the Korean obesity trial had not been published or posted by November 18, 2026. No registered trial has compared it head to head with another medicine in obesity.

The source of the cardiovascular benefit is unclear. In a 2026 mediation analysis, changes in LDL cholesterol and the urine albumin-to-creatinine ratio together explained 29.6% of the effect on major events. Weight change did not (Raaschou-Oddershede et al., 2026).

PubMed indexed no peer-reviewed animal or cell studies under efpeglenatide's name or codes on November 18, 2026. FDA's November 2026 eye-risk labeling requirement covers US GLP-1 medicine labels, and efpeglenatide has none. See FDA's GLP-1 eye-risk warning.

Frequently asked questions

Is efpeglenatide a peptide?

Partly. Its active part is a modified 39-amino-acid exendin-4 peptide, attached by a polyethylene glycol linker to a much larger human antibody Fc fragment.

Is efpeglenatide FDA-approved?

No. FDA has not approved efpeglenatide for any use.

Where is efpeglenatide approved?

South Korea's MFDS approved it on October 7, 2026, for chronic weight management in adults with obesity or overweight who do not have diabetes.

How is efpeglenatide different from exenatide and dulaglutide?

Exenatide is the exendin-4 peptide alone. Efpeglenatide modifies that peptide and links it to an IgG4 Fc fragment. Dulaglutide pairs an Fc fragment with a GLP-1 analog instead.

What did the AMPLITUDE-O trial find?

Among 4,076 adults with type 2 diabetes and heart or kidney disease, major cardiovascular events occurred in 7.0% on efpeglenatide versus 9.2% on placebo.

Why did Sanofi stop developing efpeglenatide?

Sanofi's 2020 annual report lists the program as discontinued. Trial publications say three phase 3 trials ended early for funding reasons, not safety or efficacy concerns.

Is research-labeled efpeglenatide an approved medicine?

No. The Korean approval covers Hanmi's licensed product. Material sold for laboratory research is not an approved medicine.

What to know now

  • Efpeglenatide is a modified exendin-4 peptide linked to a human IgG4 Fc fragment, developed by Hanmi Pharmaceutical.
  • AMPLITUDE-O reported fewer major cardiovascular and kidney events than placebo in high-risk adults with type 2 diabetes.
  • South Korea approved efpeglenatide for weight management in October 2026; FDA has not approved it.

What we’re watching

  • Peer-reviewed publication of the 64-week Korean obesity trial, NCT06174779.
  • Results of the Korean phase 3 diabetes trial NCT07379333, with primary completion estimated for November 2027.
  • Any regulatory filing outside Korea, including in Mexico under Hanmi's 2026 distribution agreement.

More for endocrine & metabolism

All 49 compounds for endocrine & metabolism

Sources: U.S. Food and Drug Administration 2026; Yoon 2020, Diabetes, Obesity and Metabolism, 22; Choi 2025, Frontiers in Pharmacology, 16; Hompesch 2021, BMJ Open Diabetes Research & Care, 9; Rosenstock 2019, Diabetes Care, 42; Pratley 2019, Diabetes, Obesity and Metabolism, 21; Gerstein 2021, New England Journal of Medicine, 385; Frias 2022, Diabetes Care, 45; Aroda 2023, Diabetes, Obesity and Metabolism, 25; Sanofi 2021; Hanmi Pharmaceutical 2025; Ministry of Food and Drug Safety 2026; World Anti-Doping Agency 2025; Lam 2022, Circulation, 145. All 14 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. (2026). Global Substance Registration System: efpeglenatide (UNII 3M1V5Z2270). https://precision.fda.gov/ginas/app/ui/substances/58e19849-dac4-425f-9ad7-2e51cc074bc0
  2. Yoon, K. H., Kang, J., Kwon, S. C., et al. (2020). Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 22(8), 1292-1301. https://doi.org/10.1111/dom.14032
  3. Choi, S., Seo, J., Park, S., et al. (2025). Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes. Frontiers in Pharmacology, 16, 1715585. https://doi.org/10.3389/fphar.2025.1715585
  4. Hompesch, M., Kang, J., Han, O., et al. (2021). Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study. BMJ Open Diabetes Research & Care, 9(1), e002208. https://doi.org/10.1136/bmjdrc-2021-002208
  5. Rosenstock, J., Sorli, C. H., Trautmann, M. E., et al. (2019). Once-weekly efpeglenatide dose-range effects on glycemic control and body weight in patients with type 2 diabetes on metformin or drug naive, referenced to liraglutide. Diabetes Care, 42(9), 1733-1741. https://doi.org/10.2337/dc18-2648
  6. Pratley, R. E., Kang, J., Trautmann, M. E., et al. (2019). Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study. Diabetes, Obesity and Metabolism, 21(11), 2429-2439. https://doi.org/10.1111/dom.13824
  7. Gerstein, H. C., Sattar, N., Rosenstock, J., et al. (2021). Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. New England Journal of Medicine, 385(10), 896-907. https://doi.org/10.1056/NEJMoa2108269
  8. Frias, J. P., Choi, J., Rosenstock, J., et al. (2022). Efficacy and safety of once-weekly efpeglenatide monotherapy versus placebo in type 2 diabetes: the AMPLITUDE-M randomized controlled trial. Diabetes Care, 45(7), 1592-1600. https://doi.org/10.2337/dc21-2656
  9. Aroda, V. R., Frias, J. P., Ji, L., et al. (2023). Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: the AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials. Diabetes, Obesity and Metabolism, 25(8), 2084-2095. https://doi.org/10.1111/dom.15079
  10. Sanofi. (2021). Form 20-F annual report for the fiscal year ended December 31, 2020. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1121404/000112140421000004/sny-20201231.htm
  11. Hanmi Pharmaceutical. (2025, October 27). Korea's homegrown GLP-1 obesity therapy with favorable efficacy and safety nears filing. https://www.hanmipharm.com/about/investor-relations/press/detail-3763.hm
  12. Ministry of Food and Drug Safety, Republic of Korea. (2026, October 7). MFDS approves the first domestically developed GLP-1 class obesity drug (press release, in Korean). https://www.mfds.go.kr/brd/m_99/view.do?seq=50399
  13. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
  14. Lam, C. S. P., Ramasundarahettige, C., Branch, K. R. H., et al. (2022). Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation, 145(8), 565-574. https://doi.org/10.1161/CIRCULATIONAHA.121.057934